Thoracic Malignancies

ASCO 2025

Questions discussed in this category

Will you offer lurbinectedin with atezolizumab for patients with ES-SCLC during maintenance if they had brain metastases at baseline?

Patients with baseline brain metastases were notably excluded from IMforte.

1 Answer available

What are your top takeaways in Thoracic Cancers from ASCO 2025?

12 Answers available

Papers discussed in this category

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023 Feb 03

Pembrolizumab Plus Chemotherapy in Squamous Non-Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study.

N Engl J Med, 2021-04-01

Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer.

The New England journal of medicine, 2023 Jun 03

Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer.

The New England journal of medicine, 2025 Jun 02

Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy.

The New England journal of medicine, 2025 Jun 02

Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer.

J Clin Oncol, 2022 Jun 03

Phase II Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced Non-Small-Cell Lung Cancer Previously Treated With Immunotherapy-Lung-MAP S1800A.

Lancet (London, England), 2025 Jun 02

Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial.

Related Topics in Thoracic Malignancies